Intuitive Surgical

Intuitive Surgical stands as the undisputed global leader in robotic-assisted minimally invasive surgery, transforming how surgeons perform complex procedures through innovative technology that enhances precision, visualization, and control. Founded in 1995 and headquartered in Sunnyvale, California, the company has revolutionized modern surgery with its da Vinci Surgical System, which enables surgeons to operate through tiny incisions using wristed instruments and high-definition 3D vision. The technology builds upon research conducted in the late 1980s at SRI International by Ajit Shah and Gary Guthart, with initial funding from the National Institutes of Health in 1990 to develop surgical robotics for military battlefield applications.

Since launching the first da Vinci system in 2000, Intuitive has steadily advanced the technology through multiple generations of innovation. The company's product portfolio now includes the fourth-generation da Vinci X, Xi, and SP (single-port) systems, as well as the revolutionary da Vinci 5 system, which received FDA clearance in March 2024 and features first-of-its-kind Force Feedback technology that enables surgeons to feel subtle tissue forces during surgery. The da Vinci 5 offers over 10,000 times the computing power of previous generations, improved ergonomics, and enhanced surgical sensing capabilities. Complementing the da Vinci platform is the Ion endoluminal system, launched in 2019 for robotic-assisted bronchoscopy, which allows pulmonologists to navigate an ultra-thin catheter deep into the peripheral lung for early detection and biopsy of suspicious nodules.

With 15,638 employees as of December 2024 and an installed base exceeding 10,700 da Vinci systems across 72 countries, Intuitive has established an extensive global footprint in surgical robotics. The company's systems have facilitated nearly 17 million surgical procedures to date, with approximately 2.68 million procedures performed in 2024 alone—representing 17% year-over-year growth. Intuitive's business model combines system sales with recurring revenue from instruments, accessories, and service contracts, creating strong customer relationships and predictable revenue streams. In 2024, the company reported revenue of $8.35 billion (up 17% from 2023) with a market capitalization exceeding $201 billion, making it one of the most valuable medical technology companies globally.

Intuitive made its debut on the Fortune 500 list in 2024 at #497, marking a significant milestone for the company that went public in June 2000 at $9 per share and has since delivered over 9,800% returns to shareholders. Under the leadership of CEO Gary Guthart (who will transition to Executive Chair in July 2025) and incoming CEO Dave Rosa (a 29-year company veteran), Intuitive continues to push the boundaries of surgical innovation. The company invests heavily in research and development, expanding the clinical applications of robotic surgery across specialties including urology, gynecology, general surgery, thoracic surgery, colorectal surgery, and head and neck procedures. With a culture centered on meaningful impact in healthcare, collaborative innovation, and purpose-driven work, Intuitive attracts top talent in robotics, software engineering, clinical research, and medical device development. As minimally invasive surgery becomes the standard of care for an increasing number of procedures, Intuitive is positioned to continue its trajectory as the pioneering force reshaping the future of surgery worldwide.